Moderna (MRNA) Receives U.S. FDA Approval for RSV Vaccine mRESVIA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Moderna (MRNA) PT Raised to $160 at RBC Capital
June 3, 2024 6:40 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $160.00 (from $135.00) while maintaining a Outperform rating.
The analyst comments "Despite PDUFA date pushed out by a few weeks, MRNA gets approved for RSV. Vaccine efficacy reported on the label (79%)... More
